NEW YORK (GenomeWeb News) ─ Myriad Genetics has submitted to the US Food and Drug Administration the first module of its premarket approval application for BRACAnalysis as a companion test for AstraZeneca's breast cancer PARP inhibitor olaparib.
Registering provides access to this and other free content.
Already have an account?Login Now.
Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.
The Kansas City Star examines issues surrounding newborn genome sequencing.
Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.
In Science this week: the Human Silencing Hub protein complex, and more.